|
Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
Lung Cancer
|
2018
|
NCI
|
NIH-18-017
|
|
South Carolina Research Foundation Support
|
|
|
|
$700,000
|
Lung Cancer
|
2018
|
NIEHS
|
5R01ES022968-04
|
|
Induction of Neoplastic Transformation and Cancer Stem Cells by Carbon Nanotubes
|
ROJANASAKUL, YON
|
WEST VIRGINIA UNIVERSITY
|
WV
|
$335,250
|
Lung Cancer
|
2018
|
NCI
|
5R01CA194783-04
|
|
Computational modeling of tumor burden by CT to advance cancer therapeutics
|
MAITLAND, MICHAEL
|
INOVA HEALTH CARE SERVICES
|
VA
|
$573,026
|
Lung Cancer
|
2018
|
NIGMS
|
9R44GM130155-02
|
|
Interactive Digital Media to Support Children's Learning about Tobacco and the Human Body: "Dusty the Dragon"
|
RAWITSCH, DON
|
MOAI TECHNOLOGIES, LLC
|
MN
|
$894,755
|
Lung Cancer
|
2018
|
NCI
|
5R01CA201415-02
|
|
Longitudinal Study of Adolescent Tobacco Use and Tobacco Control Policy in India
|
MISTRY, RITESH
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$543,849
|
Lung Cancer
|
2018
|
NCI
|
5F32CA200265-02
|
|
Hybrid Glycoproteomic and Autoantibody Biomarkers for Lung Cancer Early Detection
|
LASTWIKA, KRISTIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$60,278
|
Lung Cancer
|
2018
|
NIEHS
|
5R01ES005775-24
|
|
Hypoxia, DNA repair, and gene silencing
|
GLAZER, PETER
|
YALE UNIVERSITY
|
CT
|
$374,625
|
Lung Cancer
|
2018
|
NCI
|
5R01CA187392-03
|
|
Tumor-associated neutrophils in human lung cancer
|
ERUSLANOV, EVGENIY
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$366,000
|
Lung Cancer
|
2018
|
NCI
|
5R01CA124495-11
|
|
Identification and targeting of the signaling pathways underlying lung cancer.
|
KISSIL, JOSEPH
|
SCRIPPS FLORIDA
|
FL
|
$432,000
|
Lung Cancer
|
2018
|
NCI
|
5R01CA184173-04
|
|
A Limited-angle Intra-fractional Verification (LIVE) System for SBRT Treatments
|
REN, LEI
|
DUKE UNIVERSITY
|
NC
|
$363,342
|
Lung Cancer
|
2018
|
NCI
|
1K22CA212045-01A1
|
|
Tumor Macroenvironment and the Circadian Metabolic Clock
|
MASRI, SELMA
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
CA
|
$202,284
|
Lung Cancer
|
2018
|
NIGMS
|
5R01GM103790-03
|
|
Receptor and Carriers for Coupled Ion Transport
|
SESSLER, JONATHAN
|
UNIVERSITY OF TEXAS, AUSTIN
|
TX
|
$300,186
|
Lung Cancer
|
2018
|
NCI
|
5R01CA193583-03
|
|
Estrogen Signaling in a Mouse Model for Lymphangioleiomyomatosis
|
HAMMES, STEPHEN
|
UNIVERSITY OF ROCHESTER
|
NY
|
$352,275
|
Lung Cancer
|
2018
|
NCI
|
5R01CA136534-08
|
|
Structure-based anti-cancer drug development
|
DENG, XINGMING
|
EMORY UNIVERSITY
|
GA
|
$370,500
|
Lung Cancer
|
2018
|
NCI
|
5R01CA201049-03
|
|
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
|
ECK, MICHAEL
|
DANA-FARBER CANCER INST
|
MA
|
$425,882
|
Lung Cancer
|
2018
|
NCI
|
5P30CA014089-43
|
8292
|
Cancer Control Research Program (Project-005)
|
PENTZ, MARY ANN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$70,375
|
Lung Cancer
|
2018
|
NCI
|
5R01CA195227-03
|
|
Lead optimization of novel ML-IAP antagonists to treat lung cancer
|
COSFORD, NICHOLAS
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
|
CA
|
$974,339
|
Lung Cancer
|
2018
|
NCI
|
5R01CA200900-03
|
|
Systemic RNA Delivery to Tumors
|
SHI, JINJUN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$545,070
|
Lung Cancer
|
2018
|
NCI
|
5R01CA200999-04
|
|
Sex Hormones, Phytoestrogens and Lung Cancer in Female Nonsmokers
|
YANG, GONG
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$346,822
|
Lung Cancer
|
2018
|
NIMHD
|
5U01MD010648-03
|
|
Taxi STEP (Social networks, Technology, and Exercise through Pedometers)
|
GANY, FRANCESCA
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$552,836
|
Lung Cancer
|
2018
|
NCI
|
5R01CA191489-04
|
|
A novel lineage pathway controls metabolic adaptation by metastatic lung cancers
|
NGUYEN, DON
|
YALE UNIVERSITY
|
CT
|
$380,278
|
Lung Cancer
|
2018
|
NCI
|
5R01CA211125-02
|
|
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus
|
KURIE, JONATHAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$376,867
|
Lung Cancer
|
2018
|
NCI
|
5P30CA016058-42
|
5097
|
Cancer Control Research Program (CC)
|
PASKETT, ELECTRA
|
OHIO STATE UNIVERSITY
|
OH
|
$65,047
|
Lung Cancer
|
2018
|
NCI
|
5R01CA175691-05
|
|
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXL
|
TESTA, JOSEPH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$529,284
|
Lung Cancer
|
2018
|
NCI
|
5P30CA016086-42
|
8635
|
Cancer Prevention and Control Research Program (Program 8)
|
RIBISL, KURT
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$39,435
|
Lung Cancer
|
2018
|
NCI
|
5R01CA194027-03
|
|
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients
|
MARCUS, ADAM
|
EMORY UNIVERSITY
|
GA
|
$506,871
|
Lung Cancer
|
2018
|
NHLBI
|
5K08HL130666-04
|
|
The role of the long non-coding RNA Falcor in early endoderm and lung development
|
SWARR, DANIEL, T (MD)
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$162,540
|
Lung Cancer
|
2018
|
NCI
|
5R00CA197762-04
|
|
Investigating the role of the small GTPase RIT1 in lung adenocarcinoma
|
BERGER, ALICE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$249,000
|
Lung Cancer
|
2018
|
NCI
|
5U01CA190234-04
|
|
Genotype and Imaging Phenotype Biomarkers in Lung Cancer
|
AERTS, HUGO
|
DANA-FARBER CANCER INST
|
MA
|
$659,886
|
Lung Cancer
|
2018
|
NCI
|
5R01CA207375-02
|
|
The Effectiveness, Safety, and Costs of Guideline-Concordant Lung Nodule Care
|
FARJAH, FARHOOD
|
UNIVERSITY OF WASHINGTON
|
WA
|
$621,132
|
Lung Cancer
|
2018
|
NCI
|
5R01CA207500-02
|
|
Mediastinal Lymph Node Identification in Lung Cancer using NIR Fluorescent VATS
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
MA
|
$743,574
|
Lung Cancer
|
2018
|
NCI
|
5R03CA204825-02
|
|
Weight cycling and total and site-specific cancer incidence and mortality
|
GIOVANNUCCI, EDWARD
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
MA
|
$79,500
|
Lung Cancer
|
2018
|
NCI
|
5R01CA200817-03
|
|
Clinical trial personalizing radiation therapy through a novel lung function imaging modality
|
VINOGRADSKIY, YEVGENIY
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$161,657
|
Lung Cancer
|
2018
|
NCI
|
5R01CA200905-02
|
|
Modulation of BAK in Lung Cancer Therapeutics
|
DENG, XINGMING
|
EMORY UNIVERSITY
|
GA
|
$356,850
|
Lung Cancer
|
2018
|
NCI
|
5R01CA200547-02
|
|
Investigating CREBBP as a tumor suppressor in small cell lung cancer
|
MACPHERSON, DAVID
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$441,962
|
Lung Cancer
|
2018
|
NCI
|
5R01CA213448-02
|
|
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody
|
POIRIER, JOHN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$699,927
|
Lung Cancer
|
2018
|
NCI
|
5P30CA014236-44
|
5327
|
Cancer Control and Population Sciences Research Program
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
NC
|
$25,546
|
Lung Cancer
|
2018
|
NCI
|
5P30CA023108-39
|
5366
|
Cancer Control (CC)
|
SARGENT, JAMES
|
DARTMOUTH COLLEGE
|
NH
|
$72,840
|
Lung Cancer
|
2018
|
NCI
|
5R01CA203636-02
|
|
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment
|
NISHINO, MIZUKI
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$567,838
|
Lung Cancer
|
2018
|
NCI
|
5P30CA006516-53
|
5407
|
Program 13: Cancer Risk and Disparities
|
VISWANATH, KASISOMAYAJULA
|
DANA-FARBER CANCER INST
|
MA
|
$71,747
|
Lung Cancer
|
2018
|
NCI
|
5P30CA006516-53
|
5411
|
Program 34: Lung Cancer
|
JOHNSON, BRUCE
|
DANA-FARBER CANCER INST
|
MA
|
$72,325
|
Lung Cancer
|
2018
|
NIBIB
|
5R01EB020366-04
|
|
Next generation 4D-CBCT for lung cancer radiation therapy
|
WANG, JING
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$364,500
|
Lung Cancer
|
2018
|
NIEHS
|
5R01ES016893-11
|
|
Particulate Cr(VI) Toxicology in Human Lung Epithelial Cells and Fibroblasts
|
WISE, JOHN
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$350,832
|
Lung Cancer
|
2018
|
NCI
|
5R01CA091021-15
|
|
Tobacco Companies, Public Policy and Global Health
|
LEE, KELLEY
|
SIMON FRASER UNIVERSITY
|
CANADA
|
$95,386
|
Lung Cancer
|
2018
|
NCI
|
5P30CA008748-52
|
7574
|
Biostatistic
|
THOMPSON, CRAIG
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$944,194
|
Lung Cancer
|
2018
|
NCI
|
5P30CA015704-43
|
5441
|
Research Program: Global Oncology
|
CASPER, COREY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$87,209
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204173-02
|
|
DNA damage signaling to immune checkpoints
|
BAKKENIST, CHRISTOPHER
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$376,715
|
Lung Cancer
|
2018
|
NHLBI
|
5R01HL111190-06
|
|
REGULATION OF LUNG DEVELOPMENT BY FGF9 SIGNALING PATHWAYS
|
ORNITZ, DAVID
|
WASHINGTON UNIVERSITY
|
MO
|
$469,259
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204264-02
|
|
A novel point of care test for oral and oropharyngeal cancer risk
|
CALIFANO, JOSEPH
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$554,293
|
Lung Cancer
|
2018
|
NCI
|
5R01CA208403-02
|
|
A model for predicting response to PD-1 inhibitors in NSCLC
|
GARON, EDWARD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$635,258
|
Lung Cancer
|
2018
|
NIAAA
|
9R44AA027675-02
|
|
Smokescreen Translational (TL) Analysis Platform
|
BAURLEY, JAMES
|
BIOREALM
|
CA
|
$723,403
|
Lung Cancer
|
2018
|
NCI
|
5R01CA169102-06
|
|
Personalized Motion Management for truly 4D Lung Stereotactic Body Radiotherapy
|
SAWANT, AMIT
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$618,960
|
Lung Cancer
|
2018
|
NCI
|
5R01CA211052-02
|
|
Optimizing biologically-based rational polytherapy in ALK+ lung cancer
|
BIVONA, TREVER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$362,569
|
Lung Cancer
|
2018
|
NINR
|
5R01NR016694-02
|
|
Brief Behavioral Intervention for Dyspnea in Patients with Advanced Lung Cancer
|
GREER, JOSEPH
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$499,749
|
Lung Cancer
|
2018
|
NCI
|
5R01CA201340-03
|
|
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer
|
MARCUS, ADAM
|
EMORY UNIVERSITY
|
GA
|
$355,821
|
Lung Cancer
|
2018
|
NCI
|
5R01CA166480-07
|
|
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
|
KUFE, DONALD
|
DANA-FARBER CANCER INST
|
MA
|
$636,708
|
Lung Cancer
|
2018
|
NCI
|
5F30CA213765-02
|
|
Determining the Mechanisms of TWIST1-mediated Crizotinib Resistance in MET-driven Non-Small Cell Lung Carcinoma
|
YOCHUM, ZACHARY
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$49,524
|
Lung Cancer
|
2018
|
NCI
|
5R01CA205426-02
|
|
Elucidating genetics of response to immune checkpoint blockade in lung cancer
|
RIZVI, NAIYER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$558,644
|
Lung Cancer
|
2018
|
NIDA
|
5R01DA042738-02
|
|
Clean Indoor Air Laws, Cigarette Taxes, and Use of Smoking Cessation Treatments
|
RUTKOW, HELAINE
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$368,110
|
Lung Cancer
|
2018
|
NCI
|
5K07CA180782-05
|
|
The Cost-Effectiveness of Lung Cancer Screening in HIV Infection
|
SIGEL, KEITH
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
NY
|
$101,520
|
Lung Cancer
|
2018
|
NIEHS
|
5R01ES022935-05
|
|
SATB2 and Nickel Carcingenesis
|
COSTA, MAX
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$422,779
|
Lung Cancer
|
2018
|
NIEHS
|
5R01ES025515-04
|
|
Oxidative stress, Cr(VI) carcinogenesis, and prevention
|
SHI, XIANGLIN
|
UNIVERSITY OF KENTUCKY
|
KY
|
$728,875
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204004-02
|
|
Use of Alternative Tobacco Products Among Homeless Youth
|
TUCKER, JOAN
|
RAND CORPORATION
|
CA
|
$291,072
|
Lung Cancer
|
2018
|
NCI
|
5P30CA062203-21
|
4041
|
Cancer Prevention, Outcomes and Survivorship Program (CPOS)
|
WENZEL, LARI
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
CA
|
$28,545
|
Lung Cancer
|
2018
|
NCI
|
2P01CA129243-11
|
5313
|
Project 1: Mediators of Lung Adenocarcinoma Metastatis
|
MASSAGUE, JOAN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$263,445
|
Lung Cancer
|
2018
|
NCI
|
2P01CA129243-11
|
5314
|
Project 2: Targeting the ERK Pathway in KRAS- and BRAF-Driven Lung Cancers
|
ROSEN, NEAL
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$286,672
|
Lung Cancer
|
2018
|
NCI
|
2P01CA129243-11
|
5315
|
Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer
|
LOVLY, CHRISTINE
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$294,395
|
Lung Cancer
|
2018
|
NCI
|
2P01CA129243-11
|
5316
|
Project 4: Lung Cancer Drivers and Dependencies as Therapeutic Targets
|
LOWE, SCOTT
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$284,838
|
Lung Cancer
|
2018
|
NCI
|
2P01CA129243-11
|
5317
|
Administrative Core
|
KRIS, MARK
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$164,575
|
Lung Cancer
|
2018
|
NCI
|
2P01CA129243-11
|
5318
|
Core 1: Biostatistics and Bioinformatics
|
SHEN, RONGLAI
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$155,654
|
Lung Cancer
|
2018
|
NCI
|
2P01CA129243-11
|
5319
|
Core 2: Molecular Profiling and Pathology
|
LADANYI, MARC
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$276,090
|
Lung Cancer
|
2018
|
NCI
|
5R01CA197422-03
|
|
Canadian Fluoroscopy Cohort Study: Lifespan Mortality and Incidence Follow-Up
|
ZABLOTSKA, LYDIA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$669,442
|
Lung Cancer
|
2018
|
NCI
|
5F32CA206247-02
|
|
A Collaborative Reporting Tool For Interpreting Genomic Events In Lung Cancers
|
WAGNER, ALEX
|
WASHINGTON UNIVERSITY
|
MO
|
$63,034
|
Lung Cancer
|
2018
|
NCI
|
5F30CA214015-02
|
|
Development of covalent docking to identify new cysteine-targeted K-Ras inhibitors to address allelic variation in cancer
|
NNADI, CHIMNO
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$36,028
|
Lung Cancer
|
2018
|
NCI
|
5P30CA044579-27
|
5841
|
Molecular Genetics and Epigenetics Program - GEN
|
STUKENBERG, P. TODD
|
UNIVERSITY OF VIRGINIA
|
VA
|
$33,470
|
Lung Cancer
|
2018
|
NCI
|
5P30CA077598-20
|
6561
|
Analytical Biochemistry
|
YEE, DOUGLAS
|
UNIVERSITY OF MINNESOTA
|
MN
|
$165,591
|
Lung Cancer
|
2018
|
NCI
|
5P30CA077598-20
|
6562
|
(Basic Shared Resources) Analytical Biochemistry
|
YEE, DOUGLAS
|
UNIVERSITY OF MINNESOTA
|
MN
|
$120,990
|
Lung Cancer
|
2018
|
NCI
|
1R01CA221978-01
|
|
HTS for discovery of inhibitors of the centrosome-independent mitotic spindle machinery
|
ROTH, MICHAEL
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$370,575
|
Lung Cancer
|
2018
|
NCI
|
5R43CA213545-02
|
|
A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS
|
MORGAN, LEE
|
DEKK-TEC, INC.
|
LA
|
$143,294
|
Lung Cancer
|
2018
|
NCI
|
5P30CA012197-43
|
6114
|
Clinical Research (03)
|
PASCHE, BORIS
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$59,073
|
Lung Cancer
|
2018
|
NCI
|
5P30CA012197-43
|
6115
|
Cancer Prevention and Control (04)
|
PASCHE, BORIS
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$53,835
|
Lung Cancer
|
2018
|
NCI
|
5R01CA213990-02
|
|
Transcriptional Regulation of Immunosuppressive Macrophages by c-Maf in Cancer
|
YAN, JUN
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$352,275
|
Lung Cancer
|
2018
|
NCI
|
1R01CA222823-01
|
|
Resistance and Sensitivity to MET Inhibitors in Lung Cancer
|
JANNE, PASI
|
DANA-FARBER CANCER INST
|
MA
|
$390,403
|
Lung Cancer
|
2018
|
NCI
|
5F32CA213764-02
|
|
The role of neuroendocrine transdifferentiation of pancreatic cancer cells on tumor progression and chemoresistance.
|
MORRISON JOLY, MEGHAN
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$24,327
|
Lung Cancer
|
2018
|
NCI
|
1UM1CA221939-01
|
|
Center for Research to Optimize Precision Lung Cancer Screening in Diverse Populations
|
RITZWOLLER, DEBRA
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
CA
|
$3,139,491
|
Lung Cancer
|
2018
|
NCI
|
5P30CA046934-30
|
5076
|
Lung, Head & Neck Cancers Program
|
THEODORESCU, DAN
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$106,531
|
Lung Cancer
|
2018
|
NCI
|
1K08CA222625-01
|
|
Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis
|
OKIMOTO, ROSS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$177,372
|
Lung Cancer
|
2018
|
NIMHD
|
5R00MD010468-04
|
|
Applying mHealth to Tobacco-related Health Disparities: Enhancing aspects of Resiliency to aid Cessation Efforts
|
VINCI, CHRISTINE
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$249,148
|
Lung Cancer
|
2018
|
NCI
|
1K22CA222669-01
|
|
Investigating mechanistic underpinnings and therapeutic potential of selective histone deacetylase and bromodomain inhibition for the treatment of non-small cell lung cancer
|
ADEEGBE, OLAKUNLE
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$182,485
|
Lung Cancer
|
2018
|
NCI
|
5U01CA213359-02
|
|
Preclinical development of a DLL3-targeted theranostic for small cell lung cancer
|
POIRIER, JOHN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$339,331
|
Lung Cancer
|
2018
|
NCI
|
1R21CA216504-01A1
|
|
Identifying Therapeutic Vulnerabilities of c-MYC-driven Small Cell Lung Cancer
|
OLIVER, TRUDY
|
UNIVERSITY OF UTAH
|
UT
|
$165,300
|
Lung Cancer
|
2018
|
NCI
|
5R01CA081301-20
|
|
Metabolism of Carcinogenic Tobacco-Specific Nitrosamines
|
HECHT, STEPHEN
|
UNIVERSITY OF MINNESOTA
|
MN
|
$507,853
|
Lung Cancer
|
2018
|
NCI
|
5R01CA193556-03
|
|
Near infrared intraoperative molecular imaging of lung adenocarcinoma
|
SINGHAL, SUNIL
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$654,295
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204419-03
|
|
Induction of Therapeutic Immunity in the Tumor Microenvironment
|
STORKUS, WALTER
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$345,795
|
Lung Cancer
|
2018
|
NCI
|
5R01CA183594-05
|
|
Mitochondrial acetyl-CoA acetyltransferase 1 promotes the Warburg effect
|
CHEN, JING
|
EMORY UNIVERSITY
|
GA
|
$325,093
|
Lung Cancer
|
2018
|
NCI
|
5R01CA188341-04
|
|
IRS-1 Regulates Inflammatory Cell Recruitment in Lung Cancer
|
HOUGHTON, A
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$396,096
|
Lung Cancer
|
2018
|
NCI
|
5R01CA192613-04
|
|
Pemetrexed and sildenafil for lung cancer
|
DENT, PAUL
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$313,959
|
Lung Cancer
|
2018
|
NCI
|
5R01CA178061-04
|
|
Statistical Qualification of the Impact of Missing Data in EMA Studies
|
XIE, HUI
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$286,612
|
Lung Cancer
|
2018
|
NCI
|
5R01CA193532-03
|
|
Aerosol Delivery of Topotecan for Personalized Lung Cancer Therapy
|
TESSEMA, MATHEWOS
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
NM
|
$581,451
|
Lung Cancer
|
2018
|
NCI
|
5R01CA202699-03
|
|
Testing an Organizational Change Model to Address Smoking in Mental Healthcare
|
SCHNOLL, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$653,852
|
Lung Cancer
|
2018
|
NCI
|
5R01CA175360-05
|
|
The role of deubiquitinating enzyme USP33 in Slit-Robo signaling in lung cancer
|
WU, JANE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$442,825
|
Lung Cancer
|
2018
|
NCI
|
5R01CA181449-04
|
|
Interrogation of MLL2 as a tumor suppressor gene in lung cancer
|
MACPHERSON, DAVID
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$402,600
|
Lung Cancer
|
2018
|
NCI
|
5R01CA177996-05
|
|
CYCORE: Cyberinfrastructure for Cancer Comparative Effectiveness Research
|
PATRICK, KEVIN
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$139,970
|
Lung Cancer
|
2018
|
NCI
|
5F31CA203254-03
|
|
Biochemical and Functional Characterization of the Mutagenic Cytidine Deaminase APOBEC3B in the contextof Squamous Cell Lung Carcinoma
|
SASAKI, TOMOAKI
|
YALE UNIVERSITY
|
CT
|
$8,061
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204020-03
|
|
Role of GAS41 in human cancer
|
SHI, XIAOBING
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$36,600
|
Lung Cancer
|
2018
|
NCI
|
5R01CA175316-05
|
|
Transcription-dependent and -independent signaling of RSK2 in cancer metastasis
|
KANG, SUMIN
|
EMORY UNIVERSITY
|
GA
|
$323,700
|
Lung Cancer
|
2018
|
NCI
|
5R01CA174786-05
|
|
Signaling and Targeting of 6-Phosphogluconate Dehydrogenase in Human Cancers
|
CHEN, JING
|
EMORY UNIVERSITY
|
GA
|
$325,412
|
Lung Cancer
|
2018
|
NCI
|
5U24CA213274-02
|
|
Coordinating center for the NCI small cell lung cancer research consortium
|
RUDIN, CHARLES
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$1,089,718
|
Lung Cancer
|
2018
|
NCI
|
1R01CA223804-01
|
|
Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
|
YOU, MING
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$653,885
|
Lung Cancer
|
2018
|
NCI
|
1R21CA223335-01
|
|
Targeted proteomics to aid in the management of patients with stage IA lung adeno
|
BORGIA, JEFFREY
|
RUSH UNIVERSITY MEDICAL CENTER
|
IL
|
$170,738
|
Lung Cancer
|
2018
|
NCI
|
5F31CA213744-02
|
|
Mechanistic Insights into ALK Fusion Biology Through Investigation of the Fusion Partner
|
CHILDRESS, MERRIDA
|
VANDERBILT UNIVERSITY
|
TN
|
$17,026
|
Lung Cancer
|
2018
|
NCI
|
5F32CA213898-02
|
|
KLF6: A driving factor of lung adenocarcinoma
|
MCKENNA, BRIAN
|
UNIVERSITY OF VIRGINIA
|
VA
|
$28,641
|
Lung Cancer
|
2018
|
NCI
|
5R01CA121249-09
|
|
Cachexia in ApcMin/+ mice: The role of IL-6
|
CARSON, JAMES
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
SC
|
$243,653
|
Lung Cancer
|
2018
|
NCI
|
5R01CA105155-14
|
|
Regulation of Lung Cancer Metastasis by a Procollagen Lysine Hydroxylase
|
KURIE, JONATHAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$306,476
|
Lung Cancer
|
2018
|
NCI
|
5U10CA180795-05
|
|
Building upon a tradition of excellence. The NCTN at Indiana University
|
MILLER, KATHY
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$562,579
|
Lung Cancer
|
2018
|
NCI
|
5F30CA196103-04
|
|
MicroRNAs mediating Notch signaling in lung adenocarcinoma
|
MORGAN, KATHERINE
|
RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL
|
NJ
|
$49,524
|
Lung Cancer
|
2018
|
NCI
|
5R01CA203964-03
|
|
Highly multiplexed and mutation-sensitive quantitative PCR for cancer diagnostics
|
ZHANG, DAVID
|
RICE UNIVERSITY
|
TX
|
$612,394
|
Lung Cancer
|
2018
|
NCI
|
5U10CA180816-05
|
|
Stanford University NCTN- Network Lead Academic Site
|
WAKELEE, HEATHER
|
STANFORD UNIVERSITY
|
CA
|
$518,824
|
Lung Cancer
|
2018
|
NCI
|
5K99CA215244-02
|
|
Investigating the role of KLF5 genomic alterations in tumorigenesis
|
ZHANG, XIAOYANG
|
DANA-FARBER CANCER INST
|
MA
|
$133,704
|
Lung Cancer
|
2018
|
NIBIB
|
1R15EB024283-01A1
|
|
Fast and Robust Low-Dose X-Ray CT Image Reconstruction
|
ZENG, LARRY
|
WEBER STATE UNIVERSITY
|
UT
|
$273,846
|
Lung Cancer
|
2018
|
NCI
|
5U10CA180950-05
|
|
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
GA
|
$569,732
|
Lung Cancer
|
2018
|
NCI
|
1R03CA223619-01
|
|
Predicted lean body mass, fat mass, and risk of lung, pancreatic, colorectal, breast, and prostate cancers
|
GIOVANNUCCI, EDWARD
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
MA
|
$79,750
|
Lung Cancer
|
2018
|
NCI
|
1R03CA223637-01
|
|
The hexosamine biosynthesis pathway in human bronchial epithelial cell transformation.
|
CHEN, WENSHU
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
NM
|
$109,000
|
Lung Cancer
|
2018
|
NCI
|
5U01CA199240-02
|
|
Detroit Research on Cancer Survivors (Detroit ROCS)
|
SCHWARTZ, ANN
|
WAYNE STATE UNIVERSITY
|
MI
|
$1,995,543
|
Lung Cancer
|
2018
|
NCI
|
5R35CA197605-03
|
|
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$966,086
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204302-02
|
|
Characterization of YAP as a rational companion target in lung cancer
|
BIVONA, TREVER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$362,569
|
Lung Cancer
|
2018
|
NCI
|
5F30CA206339-03
|
|
EGFR rearrangements as oncogenic drivers and therapeutic targets in lung cancer
|
GALLANT, JEAN-NICOLAS
|
VANDERBILT UNIVERSITY
|
TN
|
$44,524
|
Lung Cancer
|
2018
|
NCI
|
5R01CA193396-03
|
|
Implementing Cancer Prevention Using Patient - Provider Clinical Decision Support
|
ELLIOTT, THOMAS
|
HEALTHPARTNERS INSTITUTE
|
MN
|
$607,365
|
Lung Cancer
|
2018
|
NCI
|
5R01CA208648-02
|
|
Chemoprevention of lung cancer with mitochondria-targeted honokiol
|
YOU, MING
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$627,013
|
Lung Cancer
|
2018
|
NCI
|
5R01CA185169-05
|
|
Targeting Acetyl-CoA Metabolism for the Discovery of New Anti-Cancer Therapeutics
|
MCKNIGHT, STEVEN
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$475,351
|
Lung Cancer
|
2018
|
NCI
|
5R01CA176568-05
|
|
Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes
|
GU, JIAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$494,883
|
Lung Cancer
|
2018
|
NCI
|
5R03CA215941-02
|
|
p53 mutation induces constitutive expression of interferon beta, enhancing the resistance of cancer cells to DNA damage
|
CHEON, HYEONJOO
|
CLEVELAND CLINIC LERNER COM-CWRU
|
OH
|
$79,250
|
Lung Cancer
|
2018
|
NCI
|
1R01CA214948-01A1
|
|
Targeting Metabolic Liabilities in Cancer
|
POSSEMATO, RICHARD
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$390,657
|
Lung Cancer
|
2018
|
NCI
|
5R01CA177852-04
|
|
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY
|
HANCOCK, WAYNE
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$380,640
|
Lung Cancer
|
2018
|
NCI
|
5F30CA216891-02
|
|
Investigating the role of EphA2 receptor tyrosine kinase in anti-tumor immunity mediated through programmed cell death ligand 2 (PD-L2) in non-small cell lung cancer (NSCLC)
|
SHIUAN, EILEEN
|
VANDERBILT UNIVERSITY
|
TN
|
$29,198
|
Lung Cancer
|
2018
|
NCI
|
5R01CA169259-06
|
|
Overcoming resistance to tyrosine kinase inhibitors in lung cancer
|
KOBAYASHI, SUSUMU
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$361,049
|
Lung Cancer
|
2018
|
NCI
|
5R01CA193698-04
|
|
Role of the mitochondrial citrate carrier SLC25A1(CIC)in cancer progression and therapy
|
AVANTAGGIATI, MARIA
|
GEORGETOWN UNIVERSITY
|
DC
|
$355,706
|
Lung Cancer
|
2018
|
NCI
|
1R37CA214609-01A1
|
|
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
|
GIBBONS, DON
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
Lung Cancer
|
2018
|
NCI
|
1R01CA215188-01A1
|
|
Randomized Trial of Stepped Palliative Care versus Early Integrated Palliative Care in Patients with Advanced Lung Cancer
|
TEMEL, JENNIFER
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$523,338
|
Lung Cancer
|
2018
|
NCI
|
2R01CA095039-10A1
|
|
Smoking-Induced Epigenetic Changes in the Lung: Role of DNA Demethylation
|
TRETYAKOVA, NATALIA
|
UNIVERSITY OF MINNESOTA
|
MN
|
$345,873
|
Lung Cancer
|
2018
|
NCI
|
5R01CA192399-04
|
|
Identifying tumor suppressor targets of SIRT6 in lung cancer
|
MAYO, MARTY
|
UNIVERSITY OF VIRGINIA
|
VA
|
$393,711
|
Lung Cancer
|
2018
|
NCI
|
5K07CA197221-03
|
|
Designing a Comprehensive Framework for the Evaluation of Tobacco Product Risks
|
BERMAN, MICAH
|
OHIO STATE UNIVERSITY
|
OH
|
$165,290
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204620-03
|
|
Molecular Dissection of an Arntl2 induced pro-metastatic secretome
|
WINSLOW, MONTE
|
STANFORD UNIVERSITY
|
CA
|
$367,403
|
Lung Cancer
|
2018
|
NCI
|
1R01CA214427-01A1
|
|
Implementing A Virtual Tobacco Treatment in Community Oncology Practices
|
PARK, ELYSE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$759,089
|
Lung Cancer
|
2018
|
NCI
|
1R01CA215240-01A1
|
|
Lung Screening: Efficacy versus Effectiveness
|
GAREEN, ILANA
|
BROWN UNIVERSITY
|
RI
|
$532,539
|
Lung Cancer
|
2018
|
NCI
|
1R01CA212411-01A1
|
|
Exploiting KRAS addiction for lung cancer therapy
|
CHERESH, DAVID
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$413,109
|
Lung Cancer
|
2018
|
NCI
|
5UH2CA206126-02
|
|
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients
|
WONG, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$184,223
|
Lung Cancer
|
2018
|
NCI
|
2R01CA151433-06A1
|
|
Multimodal Image-Guided Intervention System for Lung-Cancer Diagnosis and Staging
|
HIGGINS, WILLIAM
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
PA
|
$392,552
|
Lung Cancer
|
2018
|
NCI
|
1R01CA217169-01A1
|
|
BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma
|
JONES, DAVID
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$414,944
|
Lung Cancer
|
2018
|
NCI
|
2U01CA167462-06
|
|
Infrastructure Support and Pilot Tissue Collection for the CARET Biorepository
|
CHEN, CHU
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$564,986
|
Lung Cancer
|
2018
|
NCI
|
5R01CA206155-03
|
|
Crosstalk of LKB1 and KEAP1 mutations in driving growth of lung adenocarcinoma
|
BISWAL, SHYAM
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$395,755
|
Lung Cancer
|
2018
|
NCI
|
5R01CA207483-02
|
|
Markerless Motion Tracking of Lung Tumors Using Dual Energy Imaging
|
ROESKE, JOHN
|
LOYOLA UNIVERSITY CHICAGO
|
IL
|
$299,052
|
Lung Cancer
|
2018
|
NCI
|
5R01CA207763-02
|
|
The role of PCDH7 in lung cancer pathogenesis
|
O'DONNELL, KATHRYN
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$357,482
|
Lung Cancer
|
2018
|
NCI
|
5R01CA203928-02
|
|
Targeted inhibition of ribosomal RNA synthesis in LKB1-deficient cancers
|
ZHOU, WEI
|
EMORY UNIVERSITY
|
GA
|
$356,850
|
Lung Cancer
|
2018
|
NCI
|
5R33CA202867-03
|
|
High Throughput GO Chip isolation of Lung CTCs for Molecular Diagnosis and Drug Testing
|
NAGRATH, SUNITHA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$333,698
|
Lung Cancer
|
2018
|
NCI
|
5R01CA206028-03
|
|
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy
|
GEWIRTZ, DAVID
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$342,846
|
Lung Cancer
|
2018
|
NCI
|
5R01CA186729-04
|
|
Differential regulation of RNA processing by Akt isoforms
|
TSICHLIS, PHILIP
|
TUFTS MEDICAL CENTER
|
MA
|
$377,438
|
Lung Cancer
|
2018
|
NCI
|
5R01CA188743-04
|
|
Differential MRI imaging for brain tumor metastases diagnosis and treatment monitoring
|
LJUBIMOVA, JULIA
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$497,850
|
Lung Cancer
|
2018
|
NCI
|
5R21CA216650-02
|
|
Sphingosine-1-phosphate receptor subtype 3 in oncogenic K-Ras mutant-driven lung adenocarcinoma
|
LEE, MENQ-JER
|
WAYNE STATE UNIVERSITY
|
MI
|
$215,985
|
Lung Cancer
|
2018
|
NIBIB
|
5R01EB022596-02
|
|
Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiation
|
XIE, JIN
|
UNIVERSITY OF GEORGIA
|
GA
|
$476,715
|
Lung Cancer
|
2018
|
NCI
|
1K07CA215546-01A1
|
|
Electronic cigarette use in lung cancer patients
|
BRASKY, THEODORE
|
OHIO STATE UNIVERSITY
|
OH
|
$138,887
|
Lung Cancer
|
2018
|
NCI
|
1K99CA215316-01A1
|
|
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer
|
HE, JUN
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$98,086
|
Lung Cancer
|
2018
|
NIEHS
|
5R01ES014032-09
|
|
Cancer in adults following in utero and early life exposure to arsenic
|
STEINMAUS, CRAIG
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$442,424
|
Lung Cancer
|
2018
|
NCI
|
5R01CA148805-08
|
|
Role of STE20 protein kinases in malignant mesothelioma
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$434,625
|
Lung Cancer
|
2018
|
NCI
|
5K99CA215249-02
|
|
Mapping druggable co-dependency pathways in NRF2-driven lung cancers
|
BAR-PELED, LIRON
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$114,750
|
Lung Cancer
|
2018
|
NIBIB
|
5R01EB022558-03
|
|
Targeting Solid Tumors Using Nano-Engineered MSCs
|
PRABHA, SWAYAM
|
UNIVERSITY OF MINNESOTA
|
MN
|
$330,981
|
Lung Cancer
|
2018
|
NCI
|
5R01CA156744-08
|
|
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2
|
SUN, YI
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$368,125
|
Lung Cancer
|
2018
|
NCI
|
1R21CA216066-01A1
|
|
Extracellular matrix regulation of lung adenocarcinoma signaling and drug responsiveness
|
UNDERHILL, GREGORY
|
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
|
IL
|
$211,797
|
Lung Cancer
|
2018
|
NCI
|
5F30CA213817-02
|
|
Targeting lung and breast cancer cell oxidative metabolism with D-penicillamine and disulfiram
|
FALLS, KELLY
|
UNIVERSITY OF IOWA
|
IA
|
$34,592
|
Lung Cancer
|
2018
|
NCI
|
5R01CA164273-07
|
|
Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
|
SHAW, ALICE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$399,380
|
Lung Cancer
|
2018
|
NCI
|
5U01CA186157-04
|
|
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection
|
LAMPE, PAUL
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$481,475
|
Lung Cancer
|
2018
|
NCI
|
5R01CA197928-03
|
|
Small-Molecule Antagonists of Ral GTPases in Cancer
|
MEROUEH, SAMY
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$586,717
|
Lung Cancer
|
2018
|
NCI
|
5R01CA205150-03
|
|
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
|
HEYMACH, JOHN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$605,252
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204222-02
|
|
Outcomes associated with significant incidental findings in lung cancer screening
|
GAREEN, ILANA
|
BROWN UNIVERSITY
|
RI
|
$317,576
|
Lung Cancer
|
2018
|
NCI
|
1R01CA216051-01A1
|
|
The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma
|
WEISSMAN, BERNARD
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$500,167
|
Lung Cancer
|
2018
|
NCI
|
1U01CA224326-01
|
|
Studies of the initiation and progression of small cell lung cancer using cells derived by differentiation from human pluripotent stem cells
|
VARMUS, HAROLD
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$462,937
|
Lung Cancer
|
2018
|
NCI
|
5F31CA216915-02
|
|
Understanding the consequences of oncogenic mutations on FGFR signaling
|
RYAN, MOLLY
|
YALE UNIVERSITY
|
CT
|
$44,524
|
Lung Cancer
|
2018
|
NCI
|
5R01CA197486-03
|
|
Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer
|
PATEL, ABHIJIT
|
YALE UNIVERSITY
|
CT
|
$383,156
|
Lung Cancer
|
2018
|
NCI
|
5P01CA200512-03
|
8131
|
Natural History of Cigarette Smoking and Vaporized Nicotine Product Use in Countries with Different Policy Environments
|
FONG, GEOFFREY
|
UNIVERSITY OF WATERLOO
|
CANADA
|
$819,944
|
Lung Cancer
|
2018
|
NCI
|
5P01CA200512-03
|
8132
|
Nicotine and Cigarettes Across Policy Environments
|
O'CONNOR, RICHARD
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$463,467
|
Lung Cancer
|
2018
|
NCI
|
5P01CA200512-03
|
8133
|
Vaporized Nicotine Product Initiation Among Youth in the US, Canada, and England: Methods to Predict Uptake and Policy Efficacy
|
HAMMOND, DAVID
|
UNIVERSITY OF WATERLOO
|
CANADA
|
$237,722
|
Lung Cancer
|
2018
|
NCI
|
5P01CA200512-03
|
8134
|
The Experimental Tobacco Marketplace (ETM)
|
BICKEL, WARREN
|
NIH
|
|
$359,289
|
Lung Cancer
|
2018
|
NCI
|
5P01CA200512-03
|
8135
|
Modeling Industry Behavior and the Use of Vaporized Nicotine Products on Population Health
|
LEVY, DAVID
|
GEORGETOWN UNIVERSITY
|
DC
|
$186,641
|
Lung Cancer
|
2018
|
NCI
|
5U01CA213330-02
|
|
Extracellular Vesicles in Small Cell Lung Cancer Early Detection
|
NANA-SINKAM, SERGE
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$593,585
|
Lung Cancer
|
2018
|
NCI
|
5R01CA137008-09
|
|
Impact of heterogeneity on response to EGFR T790M inhibitors
|
SEQUIST, LECIA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$406,220
|
Lung Cancer
|
2018
|
NCI
|
5R01CA116020-12
|
|
Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma
|
ECK, MICHAEL
|
DANA-FARBER CANCER INST
|
MA
|
$374,063
|
Lung Cancer
|
2018
|
NCI
|
5R01CA190722-04
|
|
Targeting Anaphase Catastrophe to Combat Lung Cancer
|
KURIE, JONATHAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,425
|
Lung Cancer
|
2018
|
NCI
|
5R01CA201513-03
|
|
Notch signaling in small cell lung carcinoma
|
SAGE, JULIEN
|
STANFORD UNIVERSITY
|
CA
|
$372,322
|
Lung Cancer
|
2018
|
NCI
|
5R01CA207288-02
|
|
Development of SHP2 inhibitors for targeted anti-cancer therapy
|
ZHANG, ZHONG-YIN
|
PURDUE UNIVERSITY
|
IN
|
$469,466
|
Lung Cancer
|
2018
|
NCI
|
5R33CA202822-03
|
|
Bioengineered Lung Tumor Organoids For Development Of Personalized Medicine
|
SOKER, SHAY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$385,924
|
Lung Cancer
|
2018
|
NIDA
|
5R01DA035796-05
|
|
Advancing Tobacco Use Treatment for African American Smokers
|
COX, LISA
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$625,623
|
Lung Cancer
|
2018
|
NIDCR
|
5R01DE026013-03
|
|
Deposition Profile and Toxicology of E-Cigarettes in the Oral Epithelium
|
BELINSKY, STEVEN
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
NM
|
$545,000
|
Lung Cancer
|
2018
|
NCI
|
5F32CA210516-02
|
|
Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Lung Adenocarcinoma
|
HASTINGS, KATHERINE
|
YALE UNIVERSITY
|
CT
|
$59,038
|
Lung Cancer
|
2018
|
NCI
|
5R01CA193473-03
|
|
Integrative systems approach to identify local oncogenic modulation of the IL12 axis
|
KLINKE, DAVID
|
WEST VIRGINIA UNIVERSITY
|
WV
|
$343,125
|
Lung Cancer
|
2018
|
NCI
|
5R01CA205165-02
|
|
Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung
|
GALBIATI, FERRUCCIO
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$312,500
|
Lung Cancer
|
2018
|
NCI
|
5P30CA086862-18
|
7673
|
Program 4: Cancer Epidemiology and Population Science
|
LYNCH, CHARLES
|
UNIVERSITY OF IOWA
|
IA
|
$30,038
|
Lung Cancer
|
2018
|
NCI
|
5U24CA115091-13
|
|
University of Maryland, Baltimore Biomarker Reference Laboratory
|
STASS, SANFORD
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$575,204
|
Lung Cancer
|
2018
|
NCI
|
5R01CA194663-04
|
|
(PQC1) Accelerated biological aging and colon polyp to cancer progression
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$401,448
|
Lung Cancer
|
2018
|
NCI
|
5U01CA200495-03
|
|
Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer
|
SHOWE, LOUISE
|
WISTAR INSTITUTE
|
PA
|
$786,485
|
Lung Cancer
|
2018
|
NCI
|
5R01CA139067-07
|
|
miR-200 miRNAs repress tumor metastasis in lung adenocarcinoma
|
HE, LIN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$373,266
|
Lung Cancer
|
2018
|
NIGMS
|
5R01GM100387-06
|
|
Transfer Rule Learning with Functional Mapping for Integrative Modeling of Panomics Data
|
GOPALAKRISHNAN, VANATHI
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$292,354
|
Lung Cancer
|
2018
|
NCATS
|
2R44TR001286-02
|
|
Tools for drug efficacy studies in perfused tissue models
|
VUKASINOVIC, JELENA
|
LENA BIOSCIENCES, INC.
|
GA
|
$724,224
|
Lung Cancer
|
2018
|
NCI
|
5U10CA180868-05
|
|
NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
|
WOLMARK, NORMAN
|
NRG ONCOLOGY FOUNDATION, INC.
|
PA
|
$12,282,049
|
Lung Cancer
|
2018
|
NCI
|
5R35CA197452-04
|
|
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
|
FLORES, ELSA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$904,242
|
Lung Cancer
|
2018
|
NCI
|
5U01CA152662-08
|
|
Validation of Biomarkers of Risk for the Early Detection of Lung Cancer
|
MASSION, PIERRE
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$711,290
|
Lung Cancer
|
2018
|
NCI
|
5R01CA197936-03
|
|
Determinants of acquired resistance in small cell lung cancer
|
RUDIN, CHARLES
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$619,653
|
Lung Cancer
|
2018
|
NHLBI
|
5R01HL131907-03
|
|
PET Imaging of Pulmonary Fibrosis
|
CARAVAN, PETER
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$752,479
|
Lung Cancer
|
2018
|
NCI
|
2R44CA203058-02A1
|
|
A Computer Tool for Aiding in Accurate Assessment of Indeterminate Lung Nodules
|
MENG, XIN
|
INTERNATIONAL INTELLIGENT INFOR/SOLU/LAB
|
PA
|
$529,613
|
Lung Cancer
|
2018
|
NCI
|
1R01CA224493-01
|
|
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs
|
BOOTHMAN, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$347,128
|
Lung Cancer
|
2018
|
NCI
|
5R44CA188154-03
|
|
Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research
|
PREMSRIRUT, PREM
|
MIRIMUS, INC.
|
NY
|
$751,587
|
Lung Cancer
|
2018
|
NCI
|
1F31CA224960-01
|
|
Investigation of an ABL kinase-dependent signaling axis required for lung cancer brain metastasis
|
HOJ, JACOB
|
DUKE UNIVERSITY
|
NC
|
$44,524
|
Lung Cancer
|
2018
|
NCI
|
5R21CA208206-02
|
|
Exposure to flavored tobacco advertising and associations with future use in young adults: implications for health equity
|
ROSE, SHYANIKA
|
TRUTH INITIATIVE FOUNDATION
|
DC
|
$150,556
|
Lung Cancer
|
2018
|
NCI
|
1F31CA225119-01
|
|
Elucidating and Targeting EZH2 in the DNA Damage Response in Small Cell Lung Cancer
|
KOYEN, ALLYSON
|
EMORY UNIVERSITY
|
GA
|
$44,524
|
Lung Cancer
|
2018
|
NCI
|
1R01CA218357-01A1
|
|
Bronchoscope-guided microwave ablation of early-stage lung tumors
|
PRAKASH, PUNIT
|
KANSAS STATE UNIVERSITY
|
KS
|
$321,353
|
Lung Cancer
|
2018
|
NCI
|
1R01CA216579-01A1
|
|
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers
|
MADABHUSHI, ANANT
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$670,734
|
Lung Cancer
|
2018
|
NCI
|
1R01CA217841-01A1
|
|
A Multimedia Self-Management Intervention to Prepare Family Caregivers and Patients for Lung Cancer Surgery
|
SUN, VIRGINIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$717,367
|
Lung Cancer
|
2018
|
NCI
|
5R01CA203193-03
|
|
Comparative Effectiveness of Limited Resection vs. Stereotactic Body Radiation Therapy for Early Stage Lung Cancer
|
WISNIVESKY, JUAN
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
NY
|
$646,326
|
Lung Cancer
|
2018
|
NIEHS
|
1R01ES028600-01A1
|
|
Benzo[a]pyrene Micro-dosing of Humans: A New Tool for Exposure, Risk Assessment and Prevention
|
WILLIAMS, DAVID
|
OREGON STATE UNIVERSITY
|
OR
|
$580,890
|
Lung Cancer
|
2018
|
NCI
|
5R01CA210806-02
|
|
Optimizing Lung Cancer Treatment in HIV Infected Persons
|
SIGEL, KEITH
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
NY
|
$551,979
|
Lung Cancer
|
2018
|
NCI
|
1R01CA217165-01A1
|
|
Retail Environment for Tobacco and Marijuana in California: Impact on College Student Use
|
HENRIKSEN, LISA
|
STANFORD UNIVERSITY
|
CA
|
$664,248
|
Lung Cancer
|
2018
|
NIEHS
|
1R01ES028072-01A1
|
|
Regulation of p53 and Checkpoint Signaling by Chromium(VI)
|
ZHITKOVICH, ANATOLY
|
BROWN UNIVERSITY
|
RI
|
$365,625
|
Lung Cancer
|
2018
|
NIEHS
|
1R01ES027901-01A1
|
|
Chromium in carcinogenesis and angiogenesis
|
JIANG, BINGHUA
|
UNIVERSITY OF IOWA
|
IA
|
$320,890
|
Lung Cancer
|
2018
|
NCI
|
1UG3CA225021-01
|
|
Methods and Tools for Integrating Pathomics Data into Cancer Registries
|
SALTZ, JOEL
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
NY
|
$430,543
|
Lung Cancer
|
2018
|
NCI
|
5R01CA163591-07
|
|
Tumor Cell Dependence on Host Metabolism
|
WHITE, EILEEN
|
RUTGERS, THE STATE UNIV OF N.J.
|
NJ
|
$444,948
|
Lung Cancer
|
2018
|
NIEHS
|
5R21ES028006-02
|
|
Exosomes in Environmental Tobacco Smoke-induced Lung Cellular Senescence
|
RAHMAN, IRFAN
|
UNIVERSITY OF ROCHESTER
|
NY
|
$192,500
|
Lung Cancer
|
2018
|
NIEHS
|
5R01ES021771-05
|
|
Apoptosis resistance and Cr(VI) carcinogenesis
|
ZHANG, ZHUO
|
UNIVERSITY OF KENTUCKY
|
KY
|
$338,625
|
Lung Cancer
|
2018
|
NHLBI
|
5R01HL109031-07
|
|
Enhancing the Effectiveness of Varenicline Based Smoking Cessation Treatment
|
BAKER, TIMOTHY
|
UNIVERSITY OF WISCONSIN-MADISON
|
WI
|
$1,946,705
|
Lung Cancer
|
2018
|
NIEHS
|
5R21ES026996-02
|
|
Air Quality, Child, and Adult Health in Homes where Hookahs are Smoked
|
WEITZMAN, MICHAEL
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$254,250
|
Lung Cancer
|
2018
|
NHLBI
|
5R01HL105397-08
|
|
Genetic Association and Personalized Medicine
|
PAN, WEI
|
UNIVERSITY OF MINNESOTA
|
MN
|
$372,063
|
Lung Cancer
|
2018
|
NCI
|
1U54CA217450-01A1
|
8867
|
Modeling the SCLC Phenotypic Space
|
QUARANTA, VITO
|
VANDERBILT UNIVERSITY
|
TN
|
$564,861
|
Lung Cancer
|
2018
|
NCI
|
1U54CA217450-01A1
|
8868
|
Phenotype Interactions and Dynamics in SCLC Tumors
|
WEAVER, ALISSA
|
VANDERBILT UNIVERSITY
|
TN
|
$464,274
|
Lung Cancer
|
2018
|
NCI
|
5R01CA209818-02
|
|
Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer
|
MINKO, TAMARA
|
RUTGERS, THE STATE UNIV OF N.J.
|
NJ
|
$463,244
|
Lung Cancer
|
2018
|
NCI
|
5R01CA193935-03
|
|
The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.
|
DOEBELE, ROBERT
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$422,586
|
Lung Cancer
|
2018
|
NCI
|
5R01CA190542-04
|
|
RIP1/3 Kinases as New Targets in Malignant Mesothelioma
|
TESTA, JOSEPH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$423,359
|
Lung Cancer
|
2018
|
NCI
|
5R01CA174768-05
|
|
Understanding optimal delivery systems for cancer care
|
MILLER, DAVID
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$380,646
|
Lung Cancer
|
2018
|
NCI
|
5K07CA188142-04
|
|
Evaluating a Risk Prediction Model for Lung Cancer
|
SAKODA, LORI
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
CA
|
$192,864
|
Lung Cancer
|
2018
|
NCI
|
5R01CA190610-04
|
|
Detoxication of Air Pollutants in Humans with a Broccoli Supplement
|
GROOPMAN, JOHN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$421,934
|
Lung Cancer
|
2018
|
NCI
|
5R01CA195549-04
|
|
Novel target for therapy refractory lung tumors
|
PENDERGAST, ANN MARIE
|
DUKE UNIVERSITY
|
NC
|
$359,887
|
Lung Cancer
|
2018
|
NCI
|
5R33CA202811-03
|
|
Development and Validation of a Microdissection Method to Advance Precision Medicine in the Clinical Setting
|
JOHANN, DONALD
|
UNIV OF ARKANSAS FOR MED SCIS
|
AR
|
$385,890
|
Lung Cancer
|
2018
|
NCI
|
5R01CA197329-04
|
|
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors
|
GRAY, NATHANAEL
|
DANA-FARBER CANCER INST
|
MA
|
$540,936
|
Lung Cancer
|
2018
|
NCI
|
5R01CA184624-05
|
|
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
|
RUGGERO, DAVIDE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$359,006
|
Lung Cancer
|
2018
|
NIEHS
|
5R01ES024050-05
|
|
Recognition of Environmental Carcinogen-DNA lesions by NER Proteins
|
GEACINTOV, NICHOLAS
|
NEW YORK UNIVERSITY
|
NY
|
$353,227
|
Lung Cancer
|
2018
|
NCI
|
5R01CA198121-03
|
|
Dose-distribution radiomics to predict morbidity risk in radiotherapy
|
DEASY, JOSEPH
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$577,261
|
Lung Cancer
|
2018
|
NCI
|
5R01CA204070-04
|
|
Lung cancer in never smokers: incidence, risk factors, and molecular characteristics in Asian American, Native Hawaiian and Pacific Islanderfemales
|
GOMEZ, SCARLETT
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$675,424
|
Lung Cancer
|
2018
|
NCI
|
5R01CA206540-03
|
|
Molecular and cellular mechanisms of SCLC metastasis
|
SAGE, JULIEN
|
STANFORD UNIVERSITY
|
CA
|
$409,796
|
Lung Cancer
|
2018
|
NCI
|
5K24CA201543-03
|
|
Development of New Cancer Treatments and Investigators
|
GERBER, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$168,058
|
Lung Cancer
|
2018
|
NCI
|
5P30CA023100-32
|
6334
|
Cancer Prevention
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$22,069
|
Lung Cancer
|
2018
|
NCI
|
5R01CA193278-05
|
|
Dihydromethysticin (DHM) for Lung Cancer Chemoprevention
|
XING, CHENGGUO
|
UNIVERSITY OF FLORIDA
|
FL
|
$315,944
|
Lung Cancer
|
2018
|
NCI
|
5P30CA138292-10
|
8759
|
Cancer Prevention and Control
|
LASH, TIMOTHY
|
EMORY UNIVERSITY
|
GA
|
$82,644
|
Lung Cancer
|
2018
|
NCI
|
1U01CA225431-01
|
|
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer
|
SCHWARTZ, LAWRENCE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$644,727
|
|
|